MANAGEMENT OF SUPERFICIAL THROMBOPHLEBITIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：验证先皮下注射法格明(达肝素钠)200U/kg，然后皮下注射10000单位，每日1次，连续6天的治疗血栓性浅表性静脉炎的疗效优于布洛芬800 mg，每日3次，连续7天。特定目标1.目的：1.通过超声成像评估达肝素200单位/公斤，然后皮下注射10,000单位，每日一次或布洛芬800 mg，每日三次口服治疗的患者浅层血栓性静脉炎的发生率。在服用处方药物的同时评估疼痛的缓解程度。评估与治疗相关的出血风险。收集浅表血栓性静脉炎患者的描述性/人口学数据。对低分子肝素(Fragmin)与口服布洛芬治疗浅表性血栓性静脉炎进行药物经济学评价。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: Test the hypothesis that Fragmin (dalteparin sodium) 200 units/kg subcutaneously given at the time of presentation followed by 10,000 units given subcutaneously once daily for 6 days is more effective that Ibuprofen 800mg given orally three times daily for 7 days for the treatment of superficial thrombophlebitis. Specific Aims1. To evaluate the incidence of extension of superficial thrombophlebitis by ultrasound imaging in patients treated with dalteparin 200 units/kg at presentation followed by 10,000 units subcutaneously (sc) once daily or Ibuprofen 800mg orally three times daily.2. To evaluate the degree of pain resolution while taking the prescribed medication.3. To evaluate the risk of bleeding associated with the treatments.4. To gather descriptive/demographic data on patients with superficial thrombophlebitis.5. To perform a pharmacoeconomic assessment of treatment of superficial thrombophlebitis using low molecular weight heparin (Fragmin) versus oral ibuprofen.